CN116606758A - 一株贝莱斯芽孢杆菌及其应用 - Google Patents
一株贝莱斯芽孢杆菌及其应用 Download PDFInfo
- Publication number
- CN116606758A CN116606758A CN202310364843.9A CN202310364843A CN116606758A CN 116606758 A CN116606758 A CN 116606758A CN 202310364843 A CN202310364843 A CN 202310364843A CN 116606758 A CN116606758 A CN 116606758A
- Authority
- CN
- China
- Prior art keywords
- bacillus
- bacillus velezensis
- pathogenic bacteria
- velezensis
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000193830 Bacillus <bacterium> Species 0.000 title claims abstract description 29
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 19
- 241000193744 Bacillus amyloliquefaciens Species 0.000 claims abstract 11
- 241000588724 Escherichia coli Species 0.000 claims description 16
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 13
- 239000004098 Tetracycline Substances 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 235000019364 tetracycline Nutrition 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 11
- 241000607142 Salmonella Species 0.000 claims description 8
- 150000003522 tetracyclines Chemical class 0.000 claims description 8
- 230000003385 bacteriostatic effect Effects 0.000 claims description 6
- 229940124350 antibacterial drug Drugs 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical class CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 claims description 3
- 229940126575 aminoglycoside Drugs 0.000 claims description 3
- 229940041011 carbapenems Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229940040944 tetracyclines Drugs 0.000 claims description 3
- 150000003952 β-lactams Chemical class 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical class CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 6
- 230000003115 biocidal effect Effects 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 238000004321 preservation Methods 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 20
- 239000002609 medium Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000003042 antagnostic effect Effects 0.000 description 10
- 229960005322 streptomycin Drugs 0.000 description 10
- 229960002180 tetracycline Drugs 0.000 description 10
- 229930101283 tetracycline Natural products 0.000 description 10
- 241000563903 Bacillus velezensis Species 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 229930182566 Gentamicin Natural products 0.000 description 7
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 7
- 229960002518 gentamicin Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002689 soil Substances 0.000 description 7
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 229960004261 cefotaxime Drugs 0.000 description 6
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 6
- 229960000210 nalidixic acid Drugs 0.000 description 6
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229960001139 cefazolin Drugs 0.000 description 4
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 229960003405 ciprofloxacin Drugs 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229960000308 fosfomycin Drugs 0.000 description 4
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960004089 tigecycline Drugs 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 229940047766 co-trimoxazole Drugs 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- -1 ketone compounds Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 206010048282 zoonosis Diseases 0.000 description 2
- 241000003114 Bacillus velezensis FZB42 Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000132152 Polymyxa Species 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 241001149258 Sporobolus alterniflorus Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一株贝莱斯芽孢杆菌及其应用，所述贝莱斯芽孢杆菌为Bacillus velezensis MC2S‑6菌株，于2022年9月13日保藏在中国典型培养物保藏中心保藏，保藏号为CCTCC NO:M 20221415。本发明还公开了所述的贝莱斯芽孢杆菌在抑制多重耐药病原菌生长中的应用。本发明公开的贝莱斯芽孢杆菌，能够获得产生具有广谱、高效的抑菌物质，在抗生素耐药性问题上表现出巨大的发展前景。
Description
技术领域
本发明属于微生物技术应用领域，尤其是涉及一株贝莱斯芽孢杆菌及其应用。
背景技术
如今抗生素的广泛使用、过度使用和误用导致抗生素耐药性增加、耐药品种增加、耐药基因的水平传播等问题慢慢浮现。据估计，全球每年约有70万人死于抗生素耐药性，到2050年，死亡人数可能上升到每年1000万人。
大肠杆菌(Escherichia coli)、肺炎克雷伯菌(Klebsiella pneumoniae)、沙门氏菌(Salmonella)均为致病菌，这些细菌在胃肠道或肠外部引起广泛的疾病，影响着人类的健康。目前主要以抗菌素介导治疗，但由于细菌对各种抗菌素的耐药机制，其中包括药物作用靶位突变、水解酶或钝化酶的产生、细胞膜通透性的改变、外排泵的作用以及代谢途径的“旁路”，从而使得致病菌具有多重耐药性。这些耐药菌株适应性、致病性、定植能力、传播能力更强，而导致抗菌素耐药性全球分布。大肠杆菌、肺炎克雷伯菌、沙门氏菌的多重耐药菌株已经在全球范围内得到报道，成为一个至关重要的全球性问题。
细菌耐药性的研究成为科学领域的热点之一。因此，筛选出能够破坏多重耐药病原菌的细胞结构，导致细菌无法正常生长和繁殖，从而发挥抑菌作用的有效物质尤其重要。贝莱斯芽孢杆菌是一类产芽孢的革兰氏阳性菌，广泛分布于自然界，芽孢杆菌能产生多种抑菌活性物质，比如抗菌蛋白、脂肽类抗生素、非核糖体多肽合成酶和聚酮化合物等抗菌物质来发挥抑菌作用。
发明内容
发明目的：本发明的目的是提供了一种可抑制多种多重耐药病原菌生长的贝莱斯芽孢杆菌。本发明的另一目的是提供了贝莱斯芽孢杆菌在制备抑菌药或抗菌药中的应用。
技术方案：本发明提供了一种贝莱斯芽孢杆菌的16S rDNA基因，所述16S rDNA序列如SEQ ID NO.1所示。
本发明还提供了一株贝莱斯芽孢杆菌(Bacillus velezensis)，所述贝莱斯芽孢杆菌(Bacillus velezensis)为Bacillus velezensis MC2S-6菌株，已于2022年9月13日保藏于中国典型培养物保藏中心，保藏编号为CCTCC NO:M 20221415。
进一步地，所述贝莱斯芽孢杆菌(Bacillus velezensis)的16S rDNA序列如SEQID NO.1所示。
本发明还提供了含有上述贝莱斯芽孢杆菌(Bacillus velezensis)的菌剂。
本发明还提供了上述贝莱斯芽孢杆菌(Bacillus velezensis)或菌剂在制备抑菌药或抗菌药中的应用。
进一步地，所述抑菌药或抗菌药为抑制或拮抗多重耐药病原菌的药物。
进一步地，所述多重耐药病原菌包括沙门氏菌YZ20MCS16、肺炎克雷伯菌AH20CEAE22、大肠杆菌XYEH3934、大肠杆菌AH21MCE9和肺炎克雷伯菌AH20CAE25中的一种或几种。
进一步地，所述多重耐药病原菌耐药种类包括β-内酰胺类、碳青霉烯类、氨基糖苷类、四环素类、苯丙醇类或多粘菌素类中的一种或几种。
有益效果：与现有技术相比，本发明具有如下突出的显著优点：本发明提供的贝莱斯芽孢杆菌，能够获得产生具有广谱、高效的抑菌物质，在抗生素耐药性问题上表现出巨大的发展前景。
附图说明
图1为本发明贝莱斯芽孢杆菌的显微镜(1000X)观察照片(左)及菌落形态(右)；
图2为本发明贝莱斯芽孢杆菌基于16S rDNA基因构建的系统发育树；
图3为本发明贝莱斯芽孢杆菌16S rDNA基因的凝胶电泳结果；其中1代表Marker，2代表16S rDNA基因的产物；
图4为本发明贝莱斯芽孢杆菌对沙门氏菌YZ20MCS16的拮抗能力；
图5为本发明贝莱斯芽孢杆菌对肺炎克雷伯菌AH20CEAE22的拮抗能力；
图6为本发明贝莱斯芽孢杆菌对大肠杆菌XYEH3934的拮抗能力；
图7为本发明贝莱斯芽孢杆菌对大肠杆菌AH21MCE9的拮抗能力；
图8为本发明贝莱斯芽孢杆菌对肺炎克雷伯菌AH20CAE25的拮抗能力。
具体实施方式
下面结合附图对本发明的技术方案作进一步说明。
实施例中所用培养基及试剂：
盐溶液(g/100mL):硫酸铵3g、硫酸镁0.24g、氯化钙0.048g加入蒸馏水定容至100mL。
磷酸盐溶液(g/100mL)：磷酸二氢钾1.36g、十二水和磷酸氢二钠3.58g加入蒸馏水定容至100mL。
PYG溶液(g/100mL)：蛋白胨1g、葡萄糖1g、酵母提取物1g加入蒸馏水定容至100mL。
改良琼脂培养基PS(g/mL)：将上述盐溶液、磷酸盐溶液、PYG溶液分开高压灭菌(121℃15min)。灭菌后分别取盐溶液10mL、PYG10 mL、磷酸盐溶液100mL加入至含有15g琼脂粉定容至880ml灭菌的溶液中。
改良液体培养基PS(g/L)：将上述盐溶液、磷酸盐溶液、PYG溶液分开高压灭菌(121℃15min)。灭菌后分别取盐溶液10mL、PYG 20mL、磷酸盐溶液100mL，用灭菌蒸馏水定容至1000mL。
LB半固体培养基(g/L)：酵母提取物5g、胰化蛋白胨10g、氯化钠10g、琼脂粉8g、NaOH调pH至7.0，121℃、15min高压灭菌。
实施例1、贝莱斯芽孢杆菌的获得
1、土壤来源
江苏盐城国家级珍禽自然保护区
2、菌株的筛选
(1)土样采集
用剪刀将互花米草带土的根系剪下，轻轻抖取其上的土，用软毛刷刷取表面的土壤到新的无菌铝箔上，迅速称取土壤1g于已加入25mL生理盐水的离心管中。
(2)细菌的分离
平板稀释法：从土壤菌悬液上层中吸取1mL菌悬液，用无菌水稀释成10-3、10-4、10-5、10-6和10-7 5个不同浓度的稀释菌液。分别吸取浓度为10-3、10-4、10-5、10-6和10-75个不同浓度的稀释菌液0.2mL均匀涂布在改良琼脂培养基PS平板上。将涂布好的培养皿放置在28℃培养3d。
(3)细菌纯化
挑取不同培养性状的单菌落，采用三区划线法分离纯化，得到23株纯化单菌落依次编号并保存。
(4)细菌的保存
将上述23株纯化后的菌株分别接种在改良液体培养基PS中，在28℃、180rpm摇床中培养12h后，各吸取23株菌液0.7mL及50％的无菌甘油0.7mL于冻存管中充分混合，置于-80℃长期保存。
(5)拮抗菌的筛选
采用双层琼脂培养法：吸取拮抗菌(步骤4保存的23株菌)100μL于5mL改良液体培养基PS的试管中，28℃、180rpm摇床中培养20h，吸取20μL菌悬液于改良琼脂培养基PS中央，待晾干后放置28℃的生物培养箱中培养3d。接种5种病原菌液(沙门氏菌YZ20MCS16、肺炎克雷伯菌AH20CEAE22、大肠杆菌XYEH3934、大肠杆菌AH21MCE9和肺炎克雷伯菌AH20CAE25，均为扬州大学人兽共患病实验室分离获得)各100μL于5mL LB液体培养基中，28℃、180rpm摇床中培养16h，PBS冲洗两次，分光分度计调至OD600在0.42，将病原菌加入到冷却至50℃的LB半固培养基中，充分混匀，倒入含有拮抗菌的培养皿中，待凝固后，放置28℃的生物培养箱中培养24h，观察抑菌圈的有无，记录菌株编号并测量抑菌圈大小，整理拍照。
筛选出拮抗效果最显著的贝莱斯芽孢杆菌(Bacillus velezensis)为Bacillusvelezensis MC2S-6菌株已于2022年9月13日保藏于中国典型培养物保藏中心，保藏编号为CCTCCNO:M 20221415。通过改良琼脂培养基PS平板培养，观察菌落颜色为乳白色，凸起，圆形，表面不光滑，不透明；通过显微镜观察，该菌株的菌体为短杆状，可产生芽孢。MC2S-6的显微镜(1000X)观察照片及菌落形态如图1所示。
实施例2、贝莱斯芽孢杆菌的MC2S-6的16S rDNA基因鉴定
提取实施例1分离出的菌株MC2S-6的基因组DNA。利用引物：27F：5’
-AGAGTTTGATCCTGGCTCAG-3’(SEQ ID NO.2)和1492R：5’-TACGGCTACCTTGTTACGACTT-3’(SEQ ID NO.3)。以提取的基因组DNA为模板，进行PCR扩增，以获得目的片段。PCR反应体系如表1所示。
表1Taq聚合酶链式反应体系
PCR反应基本条件为：95℃预变性3min，95℃变性30s，56℃退火30s，72℃延伸90s(1kb/min)，72℃预延伸10min，4℃保存，共28个循环。反应结束后，PCR产物均通过1％琼脂糖凝胶电泳检验，利用凝胶成像仪检测并记录结果(见图3)。将PCR原液送北京擎科生物有限公司进行测序。序列如SEQ ID NO.1所示：GGCGACGTGCTATAATGCAAGTCGAGCGGACAGATGGGAGCTTGCTCCCTGATGTTAGCGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCTGTAAGACTGGGATAACTCCGGGAAACCGGGGCTAATACCGGATGGTTGTTTGAACCGCATGGTTCAGACATAAAAGGTGGCTTCGGCTACCACTTACAGATGGACCCGCGGCGCATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGCGACGATGCGTAGCCGACCTGAGAGGGTGATCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCGCAATGGACGAAAGTCTGACGGAGCAACGCCGCGTGAGTGATGAAGGTTTTCGGATCGTAAAGCTCTGTTGTTAGGGAAGAACAAGTGCCGTTCAAATAGGGCGGCACCTTGACGGTACCTAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGGGCTCGCAGGCGGTTTCTTAAGTCTGATGTGAAAGCCCCCGGCTCAACCGGGGAGGGTCATTGGAAACTGGGGAACTTGAGTGCAGAAGAGGAGAGTGGAATTCCACGTGTAGCGGTGAAATGCGTAGAGATGTGGAGGAACACCAGTGGCGAAGGCGACTCTCTGGTCTGTAACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAGTGCTAAGTGTTAGGGGGTTTCCGCCCCTTAGTGCTGCAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGGTCGCAAGACTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCCTCTGACAATCCTAGAGATAGGACGTCCCCTTCGGGGGCAGAGTGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGATCTTAGTTGCCAGCATTCAGTTGGGCACTCTAAGGTGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGACAGAACAAAGGGCAGCGAAACCGCGAGGTTAAGCCAATCCCACAAATCTGTTCTCAGTTCGGATCGCAGTCTGCAACTCGACTGCGTGAAGCTGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCACGAGAGTTTGTAACACCCGAAGTCGGTGAGGTAACCTTTTAGGAGCCAGCCGCCGAAGTGAACAG。测序结果运用SeqMan进行分析，并在NCBI网站上进行BLAST比对，确定近缘株细菌的种属。结果显示：菌株MC2S-6的16S rDNA基因与Bacillus velezensis FZB42具有99.58％的相似度，分类命名为贝莱斯芽孢杆菌Bacillusvelezensis MC2S-6。使用MEGA6.0构建持假基因的系统发育树，结果见图2。
实施例3、贝莱斯芽孢杆菌MC2S-6的生理生化鉴定
本发明的贝莱斯芽孢杆菌MC2S-6的生理生化特征为：能够利用甘油、葡萄糖、果糖、甘露糖、肌醇、甘露醇、山梨醇等15种碳源，见表2。
表2贝莱斯芽孢杆菌MC2S-6的生理生化鉴定
注：+：阳性反应；-：阴性反应
实施例4、贝莱斯芽孢杆菌MC2S-6的拮抗谱测定
贝莱斯芽孢杆菌MC2S-6对5株具有多重耐药性病原菌的拮抗活性测定。
将实施例1获得的接种贝莱斯芽孢杆菌MC2S-6(拮抗菌)100μL于5mL改良液体培养基PS中，28℃、180rpm摇床中培养20h，吸取20μL菌悬液于改良琼脂培养基PS中央，待晾干后倒板于28℃的生化培养箱中培养3d，吸取5种病原菌(沙门氏菌YZ20MCS16、肺炎克雷伯菌AH20CEAE22、大肠杆菌XYEH3934、大肠杆菌AH21MCE9、肺炎克雷伯菌AH20CAE25)菌液100μL于5mL LB液体培养基中，28℃、180rpm摇床中培养16h，用PBS冲洗两次，用分光分度计调至OD600在0.42，将病原菌分别加入到冷却至50℃的LB半固培养基中，充分混匀，倒入含有拮抗菌的培养皿中，待凝固后，放置28℃的生化培养箱中培养24h，观察抑菌圈的有无，记录菌株编号并测量抑菌圈大小，整理拍照。结果如图4-8、表3所示。结果表明，贝莱斯芽孢杆菌MC2S-6能够抑制5株多重耐药菌株的生长，其中对大肠杆菌XYEH3934的抑制效果最佳，而对肺炎克雷伯AH20CEAE22的抑制效果较弱。
表3莱斯芽孢杆菌MC2S-6对5株多重耐药致病菌的抑菌效果的数据
其中，5种病原菌均为扬州大学人兽共患病实验室分离获得，沙门菌YZ20MCS16(GenBank：PRJNA740125)对氨苄西林(AMP)、头孢唑林(CFZ)、头孢噻肟(CTX)、庆大霉素(GEN)、链霉素(STR)、四环素(TET)、萘啶酸(NAL)、环丙沙星(CIP)、复方新诺明(SXT)表现出耐药。肺炎克雷伯菌AH20CEAE22对氨苄西林(AMP)、头孢唑林(CFZ)、头孢噻肟(CTX)、庆大霉素(GEN)、美西林(AMI)、链霉素(STR)、四环素(TET)、氯霉素(CHL)、氟苯尼(FFC)、萘啶酸(NAL)、环丙沙星(CIP)、磷霉素(FOS)、复方新诺明(SXT)表现出耐药。大肠杆菌XYEH3934(GenBank：PRJNA901528)对氨苄西林(AMP)、头孢噻肟(CTX)、链霉素(STR)、四环素(TET)、替加环素(TIL)、氯霉素(CHL)、氟苯尼(FFC)、萘啶酸(NAL)、磷霉素(FOS)、复方新诺明(SXT)表现出耐药。大肠杆菌AH21MCE9对头孢噻肟(CTX)、多粘菌素(CL)表现出耐药。肺炎克雷伯菌AH20CAE25对替加环素(TIL)、氨苄西林(AMP)、头孢唑林(CFZ)、庆大霉素(GEN)、美西林(AMI)、链霉素(STR)、四环素(TET)、庆大霉素(GEN)、美西林(AMI)、链霉素(STR)、四环素(TET)表现出耐药。
本实施例使用的病原菌中的大肠杆菌、沙门菌及肺炎克雷伯菌均表现出对β-内酰胺类、碳青霉烯类、氨基糖苷类、四环素类、苯丙醇类、多粘菌素类几大类抗生素具有耐药性，这5株肠道致病菌均为多重耐药菌株。
Claims (8)
1.一种贝莱斯芽孢杆菌的16S rDNA，其特征在于，所述16S rDNA序列如SEQ ID NO.1所示。
2.一株贝莱斯芽孢杆菌(Bacillus velezensis)，其特征在于，所述贝莱斯芽孢杆菌(Bacillus velezensis)为Bacillus velezensis MC2S-6菌株，已于2022年9月13日保藏于中国典型培养物保藏中心，保藏编号为CCTCC NO:M 20221415。
3.根据权利要求2所述的贝莱斯芽孢杆菌(Bacillus velezensis)，其特征在于，所述贝莱斯芽孢杆菌(Bacillus velezensis)的16S rDNA序列如SEQ ID NO.1所示。
4.一种含有权利要求1或2所述的贝莱斯芽孢杆菌(Bacillus velezensis)的菌剂。
5.一种权利要求1或2所述的贝莱斯芽孢杆菌(Bacillus velezensis)或权利要求3所述的菌剂在制备抑菌药或抗菌药中的应用。
6.根据权利要求5所述的应用，其特征在于，所述抑菌药或抗菌药为抑制或拮抗多重耐药病原菌的药物。
7.根据权利要求6所述的应用，其特征在于，所述多重耐药病原菌包括沙门氏菌YZ20MCS16、肺炎克雷伯菌AH20CEAE22、大肠杆菌XYEH3934、大肠杆菌AH21MCE9和肺炎克雷伯菌AH20CAE25。
8.根据权利要求6所述的应用，其特征在于，所述多重耐药病原菌耐药种类包括β-内酰胺类、碳青霉烯类、氨基糖苷类、四环素类、苯丙醇类或多粘菌素类中的一种或几种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310364843.9A CN116606758A (zh) | 2023-04-07 | 2023-04-07 | 一株贝莱斯芽孢杆菌及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310364843.9A CN116606758A (zh) | 2023-04-07 | 2023-04-07 | 一株贝莱斯芽孢杆菌及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116606758A true CN116606758A (zh) | 2023-08-18 |
Family
ID=87680739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310364843.9A Pending CN116606758A (zh) | 2023-04-07 | 2023-04-07 | 一株贝莱斯芽孢杆菌及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116606758A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118667696A (zh) * | 2024-06-17 | 2024-09-20 | 吉林农业大学 | 一株贝莱斯芽孢杆菌fs-3和所产的细菌素及应用 |
| TWI872667B (zh) * | 2023-08-28 | 2025-02-11 | 國立中山大學 | 貝萊斯芽孢桿菌ｍ４０１９、其醱酵萃取液、其製造方法、含其之淋病抑制劑及其用於製備抑制淋病之組成物的用途 |
-
2023
- 2023-04-07 CN CN202310364843.9A patent/CN116606758A/zh active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI872667B (zh) * | 2023-08-28 | 2025-02-11 | 國立中山大學 | 貝萊斯芽孢桿菌ｍ４０１９、其醱酵萃取液、其製造方法、含其之淋病抑制劑及其用於製備抑制淋病之組成物的用途 |
| CN118667696A (zh) * | 2024-06-17 | 2024-09-20 | 吉林农业大学 | 一株贝莱斯芽孢杆菌fs-3和所产的细菌素及应用 |
| CN118667696B (zh) * | 2024-06-17 | 2025-03-14 | 吉林农业大学 | 一株贝莱斯芽孢杆菌fs-3和所产的细菌素及应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Semenec et al. | Cross-protection and cross-feeding between Klebsiella pneumoniae and Acinetobacter baumannii promotes their co-existence | |
| Rossi et al. | Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis | |
| Penesyan et al. | Antimicrobial activity observed among cultured marine epiphytic bacteria reflects their potential as a source of new drugs | |
| CN112940982B (zh) | 一株鳢源贝莱斯芽孢杆菌及其应用 | |
| CN116606758A (zh) | 一株贝莱斯芽孢杆菌及其应用 | |
| CN112195158B (zh) | 一株裂解性副溶血性弧菌噬菌体rdp-vp-19003及其应用 | |
| CN113186136B (zh) | 一种多重耐药的幽门螺旋杆菌及其应用 | |
| KR101201420B1 (ko) | 신규 락토바실러스 존슨니 및 이를 포함하는 사료첨가제 조성물 | |
| Han et al. | Stenotrophomonas strain CPCC 101271, an intestinal lifespan-prolonging bacterium for Caenorhabditis elegans that assists in host resistance to “Bacillus nematocida” colonization | |
| KR101201337B1 (ko) | 신규한 락토바실러스속 유산균 복합 균주를 포함하는 사료첨가제 | |
| Shi et al. | Antagonistic activity and mechanism of Lactobacillus rhamnosus SQ511 against Salmonella enteritidis | |
| Fang et al. | Characterization of a Plant Growth-Promoting Endohyphal Bacillus subtilis in Fusarium acuminatum from Spiranthes sinensis | |
| CN114854632B (zh) | 一株海藻来源的共生盐孢菌hz014及其应用 | |
| CN118207108A (zh) | 一株双向伯克霍尔德氏菌dc13及其用途 | |
| de Wet et al. | Uncovering antibiotic resistance: extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa from dipteran flies in residential dumping and livestock environments | |
| CN119331783B (zh) | 一种肠炎韦荣氏球菌及其应用 | |
| RU2822363C1 (ru) | Штамм бактерий Sporosarcina psychrophila - продуцент антимикробных соединений | |
| Rahman et al. | Genomic and In Vitro Analysis of Pediococcus pentosaceus MBBL4 Implicated Its Therapeutic Use Against Mastitis Pathogens and as a Potential Probiotic | |
| Pompilio et al. | Microbial biofilm: a “sticky” problem | |
| Semenec et al. | Cross-protection and cross-feeding between ESKAPE pathogens Klebsiella pneumoniae and Acinetobacter baumannii promotes their co-existence | |
| CN113186128B (zh) | 一株链球菌新种及其应用 | |
| CN114606206B (zh) | 具有特异性杀伤肠出血性大肠杆菌的工程λ噬菌体及其构建方法和应用 | |
| Lott | Molecular mechanisms underpinning intraspecies co-infections with multiple Acinetobacter baumannii strains | |
| CN119913069A (zh) | 一种嗉囊粘液乳杆菌pn5及其应用 | |
| Ansari et al. | Screening of antagonistic activity in different Streptomyces species against Paecilomyces variotii and verification of some of the physiological properties of the antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |